Discovery of novel CYP17 inhibitors for the treatment of prostate cancer with structure-based drug design

Letters in Drug Design and Discovery

Volumn 6, Issue 5, 2009, Pages 337-344

  Armutlu, Pelin ^a   Özdemir, Muhuttin Emre ^a   Özdaş, Şule ^a   Kavakli, Ibrahim Halil ^a   Türkay, Metin ^a  

^a KOÇ UNIVERSITY   (Turkey)

Author keywords

20 Lyase; Androgen biosynthesis; Cytochrome P450 enzyme 17R hydroxylase 17; Prostate cancer; Virtual screening

Indexed keywords

ANTINEOPLASTIC AGENT; CYTOCHROME P450 17; NONSTEROID CYTOCHROME P450 17 INHIBITOR; OXIDOREDUCTASE INHIBITOR; STEROID CYTOCHROME P450 17 INHIBITOR; UNCLASSIFIED DRUG;

ARTICLE; CANCER CHEMOTHERAPY; COMPUTER SYSTEM; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG DESIGN; DRUG DETERMINATION; EMBRYO; ENZYME ACTIVITY; ENZYME INHIBITION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROSTATE CANCER; STRUCTURE ACTIVITY RELATION;

EID: 67650555893     PISSN: 15701808     EISSN: None     Source Type: Journal    
DOI: 10.2174/1570180810906050337     Document Type: Article

References (24)

1. Mettlin, C. Recent developments in the epidemiology of prostate cancer. Eur. J. Cancer, 1997, 33, 340-347.
2. Pomerantz, M.; Kantoff, P. Advances in the treatment of prostate cancer. Annu. Rev. Med., 2007, 58, 205-220.
3. Hartmann, R. W.; Ehmer, P. B.; Haidar, S.; Hector, M.; Jose, J.; Klein, C. D. P.; Seidel, S. B.; Sergejew, T. F.; Wachall, B. G.; Wachter, G. A.; Zhuang, Y. Inhibition of CYP 17, a new strategy for the treatment of prostate cancer. Archiv. Der. Pharmazie, 2002, 335, 119-128.
4. Arlt, W.; Neogi, P.; Gross, C.; Miller, W. L. Cinnamic acid based thiazolidinediones inhibit human P450c17 and 3 betahydroxysteroid dehydrogenase and improve insulin sensitivity independent of PPAR gamma agonist activity. J. Mol. Endocrinol., 2004, 32, 425-436.
5. Neumann, F. The antiandrogen cyproterone-acetate - discovery, chemistry, basic pharmacology, clinical use and tool in basic research. Exp. Clin. Endocrinol., 1994, 102, 1-32.
6. Grigoryev, D. N.; Kato, K.; Njar, V. C. O.; Long, B. J.; Ling, Y. Z.; Wang, X.; Mohler, J.; Brodie, A. M. H. Cytochrome P450c17-expressing Escherichia coli as a first-step screening system for 17 alpha-hydroxylase-C-17,C-20-lyase inhibitors. Anal. Biochem., 1999, 267, 319-330.
7. Clement, O. O.; Freeman, C. M.; Hartmann, R. W.; Handratta, V. D.; Vasaitis, T. S.; Brodie, A. M. H.; Njar, V. C. O. Three dimensional pharmacophore modeling of human CYP17 inhibitors. Potential agents for prostate cancer therapy. J. Med. Chem., 2003, 46, 2345-2351.
8. Madan, R. A.; Arlen, P. M. Abiraterone - cougar biotechnology. Idrugs, 2006, 9, 49-55.
9. Arlt, W.; Auchus, R. J.; Miller, W. L. Thiazolidinediones but not metformin directly inhibit the steroidogenic enzymes P450c17 and 3 beta-hydroxysteroid dehydrogenase. J. Biol. Chem., 2001, 276, 16767-16771.
10. Handratta, V. D.; Vasaitis, T. S.; Njar, V. C. O.; Gediya, L. K.; Kataria, R.; Chopra, P.; Newman, D.; Farquhar, R.; Guo, Z. Y.; Qiu, Y.; Brodie, A. M. H. Novel C-17-heteroaryl steroidal CYP17 inhibitors/antiandrogens: Synthesis, in vitro biological activity, pharmacokinetics, and antitumor activity in the LAPC4 human prostate cancer xenograft model. J. Med. Chem., 2005, 48, 2972-2984.
11. Ideyama, Y.; Kudoh, M.; Tanimoto, K.; Susaki, Y.; Nanya, T.; Nakahara, T.; Ishikawa, H.; Fujikura, T.; Akaza, H.; Shikama, H. YM116, 2-(1H-imidazol-4-ylmethyl)-9H-carbazole, decreases adrenal androgen synthesis by inhibiting C17-20 lyase activity in NCI-H295 human adrenocortical carcinoma. Jpn. J. Pharmacol., 1999, 79, 213-220.
12. Nnane, I. P.; Kato, K.; Liu, Y.; Long, B. J.; Lu, Q.; Wang, X.; Ling, Y. Z.; Brodie, A. Inhibition of androgen synthesis in human testicular and prostatic microsomes and in male rats by novel steroidal compounds. Endocrinology, 1999, 140, 2891-2897. (Pubitemid 32245171)
13. Moreira, V. M.; Salvador, J. A. R.; Vasaitis, T. S.; Njar, V. C. O. CYP17 inhibitors for prostate cancer treatment - An update. Curr. Med. Chem., 2008, 15, 868-899.
14. Auchus, R. J.; Miller, W. L. Molecular modeling of human P450c17 (17 alpha-hydroxylase/17,20-lyase): Insights into reaction mechanisms and effects of mutations. Mol. Endocrinol., 1999, 13, 1169-1182.
15. Laughton, C. A.; Neidle, S.; Zvelebil, M. J. J. M.; Sternberg, M. J. E. A molecular-model for the enzyme cytochrome-P45017-alpha, a major target for the chemotherapy of prostatic-cancer. Biochem. Biophys. Res. Commun., 1990, 171, 1160-1167.
16. Lin, D.; Zhang, L. H.; Chiao, E.; Miller, W. L. Modeling and Mutagenesis of the Active-Site of Human P450C17. Mol. Endocrinol., 1994, 8, 392-402.
17. Collins, J. R.; Camper, D. L.; Loew, G. H. Valproic acid metabolism by cytochrome-P450 - a theoretical-study of stereoelectronic modulators of product distribution. J. Am. Chem. Soc., 1991, 113, 2736-2743.
18. Morris, G. M.; Goodsell, D. S.; Halliday, R. S.; Huey, R.; Hart, W. E.; Belew, R. K.; Olson, A. J. Automated docking using a Lamarckian genetic algorithm and an empirical binding free energy function. J. Comput. Chem., 1998, 19, 1639-1662.
19. Sambrook, J. E.; Rusell, D. V. Molecular Cloning: A Laboratory Manual, Cold Spring Harbor: New York, 2001.
20. Grigoryev, D. N.; Long, B. J.; Nnane, I. P.; Njar, V. C. O.; Liu, Y.; Brodie, A. M. H. Effects of new 17 alpha-hydroxylase/C-17,C-20- lyase inhibitors on LNCaP prostate cancer cell growth in vitro and in vivo. Br. J. Cancer, 1999, 81, 622-630.
21. Kibaly, C.; Patte-Mensah, C.; Mensah-Nyagan, A. G. Molecular and neurochemical evidence for the biosynthesis of dehydroepian-drosterone in the adult rat spinal cord. J. Neurochem., 2005, 93, 1220-1230. (Pubitemid 40778684)
22. Akhtar, M.; LeeRobichaud, P.; Akhtar, M. E.; Wright, J. N. The impact of aromatase mechanism on other P450s. J. Steroid Biochem. Mol. Biol., 1997, 61, 127-132.
23. Benbow, J. W.; Bernberg, E. L.; Korda, A.; Mead, J. R. Synthesis and evaluation of dinitroanilines for treatment of cryptosporidiosis. Antimicrob. Agents Chemother., 1998, 42, 339-343.
24. Armutlu, P.; Ozdemir, M. E.; Uney-Yuksektepe, F.; Kavakli, I. H.; Turkay, M. Classification of drug molecules considering their IC50 values using mixed-integer linear programming based hyper-boxes method. BMC Bioinformatics, 2008, 9, 411.